Sofinnova Partners, one of Europe’s leading life sciences venture capital firms, has closed Sofinnova Capital XI at €650 million ($750 million) — well above its initial target.
With offices in Paris, London, and Milan, the new flagship fund will back early-stage biopharmaceutical and medical technology companies developing solutions for major unmet medical needs. Capital XI is already active, with early investments in Latent Labs, BioCorteX, and Amolyt.
Capital XI builds on Sofinnova’s multi-strategy platform and will draw on the expertise of partners Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter, and Graziano Seghezzi.
The fund received strong support from top-tier institutional investors around the world — including sovereign wealth funds, pharmaceutical companies, insurance firms, corporates, foundations, and family offices across Europe, North America, Asia, and the Middle East. Both longstanding LPs and new global backers participated, underscoring continued confidence in Sofinnova’s approach and track record.
Advertisement
Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, commented:
“This fundraise is a defining milestone for Sofinnova. It gives us the capital to further strengthen our commitment to early-stage innovation and reinforces our collaborative, science-first strategy. We’re proud to support visionary founders and help the next wave of scientific and medical breakthroughs reach patients around the world.”
Sofinnova Capital XI will continue investing in early-stage biotech and medtech companies across Europe and North America, supporting both new portfolio additions and follow-on rounds.
About Sofinnova Partners
Founded in 1972, Sofinnova Partners is a leading European life sciences venture capital firm focused on healthcare and sustainability. With offices in Paris, London, and Milan, the firm partners with entrepreneurs at every stage to build category-defining companies. Sofinnova manages more than €4 billion and has supported over 500 innovators worldwide.
